Carisma Therapeutics, Inc. (CARM)
OTCMKTS · Delayed Price · Currency is USD
0.0022
-0.0023 (-51.11%)
At close: Jul 29, 2026

Carisma Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
52.6319.6314.929.83--
Revenue Growth
159.68%31.59%51.71%---
Gross Profit
25.28-40.04-59.21-46.78-34.39-
Operating Income
12.85-60.18-88.73-56.16-40.79-28.38
Net Income
8.04-60.48-86.88-61.23-40.78-28.35
Earnings Per Share
0.19-1.46-2.59-28.77-37.62-26.66
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
2.7818.8378.55228.5551.79
Total Debt
0.762.483.1240.162.633.45
Net Cash (Debt)
2.0216.3575.3711.8325.9248.34
Net Cash Growth
-91.88%-78.30%537.03%-54.35%-46.38%-
Net Cash Per Share
0.050.392.255.5623.9145.46

Cash Flow & CapEx

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-22.42-59.92-81.18-5.12-37.33-27.01
Capital Expenditures
--0.12-1.13-4.66-1.87-0.44
Free Cash Flow
-22.42-60.04-82.31-9.78-39.2-27.45
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
48.03%-203.96%----
Operating Margin
24.41%-306.54%-594.75%-571.10%--
Pretax Margin
15.28%-308.05%-582.34%-622.60%--
Profit Margin
15.28%-308.05%-582.34%-622.60%--
FCF Margin
-42.59%-305.83%-551.71%-99.41%--

Valuation

Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingJul '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
0.000.897.93---